Medicines

Oncology
Rising to cancer’s challenge
Cancer care in emerging markets faces challenges in access and affordability. Abbott is expanding access to biologic oncology treatments, helping more people receive life-changing therapies. Through strategic partnerships and local innovation, we’re committed to bringing advanced cancer care to more communities in emerging markets.
Women’s Health
Health at every stage of life
What makes Abbott a global leader in women’s health? We improve access to high-quality medicines for hard-to-treat diseases such as osteoporosis, breast cancer and menstrual disorders. We foster open dialogue about menopause, and we support women throughout their pregnancy. We also understand how cardiovascular disease and other conditions affect women differently. Everything we do shares a common purpose: supporting women’s health at every stage of their life and help them achieve their full potential.
Medication adherence
Better behaviors for better health
We all know that medicines only keep us healthy if we take them. But the reality is that around half of us don’t take our medicines as prescribed,1 and one-third never fill their prescriptions.2,3 Globally, this is a massive medical challenge that keeps people from living their healthiest lives.

A:CARE is our pioneering program developed with the brightest brains in behavioral science, which focuses on education, insights, and coaching to support healthcare professionals and help people better stick to their treatment so that they can live healthier lives.

Featured Medicines

Our medicines business aims to meet the health needs of countries where getting to see a doctor can be challenging. We are solely focused on emerging markets, and we have deep insight into the unique health challenges and needs of local communities in the world’s fastest-growing countries.

This page is intended for general informational purposes only and does not replace professional medical advice. Product availability, indications, and labelling may vary by country. Always consult your healthcare provider and refer to the locally approved product information..

Products

Brufen®

Our nonsteroidal anti-inflammatory drug used to relieve pain, reduce inflammation and lower fever.

Products

Resyniv®

A denosumab biosimilar medicine for the osteoporosis treatment in postmenopausal women and in men at increased risk of fractures

Products

Femoston®

A medication used as an HRT (Hormone Replacement Therapy) in postmenopausal women.

Products

Creon®

Helping people suffering from cystic fibrosis or pancreatic cancer with food digestion.

Medicines for emerging markets around the world

Every day, more than 64 million people around the world live healthier lives with Abbott’s medicines products. Our portfolio, available in emerging markets only, helps people get and stay healthy through trusted, high-quality medicines.

We focus on women’s health, cardiometabolic conditions, gastroenterology, oncology, immunology and more, with a tailored approach that reflects local needs and delivers accessible, reliable solutions.

We leverage our footprint in emerging countries and scientific heritage to offer more medicines that are superior to available alternatives, backed by strong scientific evidence. Whether it’s an ordinary headache or a more serious illness, we want people to get better fast, so they can go back to doing the things they love.

Biosimilars: Improving global access
Biosimilars are transforming access to advanced treatments for serious conditions like cancer. At Abbott, we partner with leading biotech innovators to deliver high-quality biosimilars in emerging markets — making biologic therapies more affordable and accessible. Our commitment is to remove barriers to care and help more people live healthier lives.

The biosimilars story

Biosimilars are approved according to local regulatory standards and may not be interchangeable with reference products.

Related articles

References

1Hichborn J, et al. Improving patient adherence through data-driven insights. McKinsey & Company. 2018. Available at: https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/improving-patient-adherence-through-data-driven-insights

2Fischer MA, Stedman MR, Lii J, et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med. 2010;25(4):284-290.

3Organisation for Economic Co-operation and Development. OECD Health Working Paper No. 105 Investing in medication adherence improves health outcomes and health system efficiency – Adherence to medicines for diabetes, hypertension, and hyperlipidaemia. 2018. Available at: http://www.Oecd.Org/Officialdocuments/Publicdisplaydocumentpdf/?Cote=DELSA/HEA/WD/HWP(2018)2&Doclanguage=En>

Products and Solutions

Need Help?

© 2026 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are approved for use in the U.S. only and are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.